Surgery--a  ||| S:0 E:11 ||| JJ
challenge  ||| S:11 E:21 ||| NN
in  ||| S:21 E:24 ||| IN
haemophiliacs  ||| S:24 E:38 ||| NN
with  ||| S:38 E:43 ||| IN
inhibitors  ||| S:43 E:54 ||| JJ
Treatment  ||| S:54 E:64 ||| NNP
of  ||| S:64 E:67 ||| IN
haemophiliacs  ||| S:67 E:81 ||| NN
with  ||| S:81 E:86 ||| IN
inhibitors  ||| S:86 E:97 ||| NN
is  ||| S:97 E:100 ||| VBZ
of  ||| S:100 E:103 ||| IN
great  ||| S:103 E:109 ||| JJ
concern  ||| S:109 E:117 ||| NN
in  ||| S:117 E:120 ||| IN
low-income  ||| S:120 E:131 ||| JJ
countries  ||| S:131 E:141 ||| NNS
confronting  ||| S:141 E:153 ||| VBG
shortage  ||| S:153 E:162 ||| NN
in  ||| S:162 E:165 ||| IN
substitutive  ||| S:165 E:178 ||| JJ
treatment ||| S:178 E:187 ||| NN
.  ||| S:187 E:189 ||| .
Invasive  ||| S:189 E:198 ||| JJ
interventions  ||| S:198 E:212 ||| NNS
on  ||| S:212 E:215 ||| IN
these  ||| S:215 E:221 ||| DT
patients  ||| S:221 E:230 ||| NNS
represent  ||| S:230 E:240 ||| VBP
a  ||| S:240 E:242 ||| DT
major  ||| S:242 E:248 ||| JJ
challenge  ||| S:248 E:258 ||| NN
due  ||| S:258 E:262 ||| JJ
to  ||| S:262 E:265 ||| TO
the  ||| S:265 E:269 ||| DT
fact  ||| S:269 E:274 ||| NN
that  ||| S:274 E:279 ||| IN
costs  ||| S:279 E:285 ||| NNS
are  ||| S:285 E:289 ||| VBP
significantly  ||| S:289 E:303 ||| RB
higher  ||| S:303 E:310 ||| JJR
in  ||| S:310 E:313 ||| IN
comparison  ||| S:313 E:324 ||| NN
to  ||| S:324 E:327 ||| TO
similar  ||| S:327 E:335 ||| JJ
procedures  ||| S:335 E:346 ||| NNS
conducted  ||| S:346 E:356 ||| VBN
on  ||| S:356 E:359 ||| IN
patients  ||| S:359 E:368 ||| NNS
without  ||| S:368 E:376 ||| IN
inhibitors ||| S:376 E:386 ||| NN
.  ||| S:386 E:388 ||| .
In  ||| S:388 E:391 ||| IN
the  ||| S:391 E:395 ||| DT
context  ||| S:395 E:403 ||| NN
of  ||| S:403 E:406 ||| IN
insufficient  ||| S:406 E:419 ||| JJ
availability  ||| S:419 E:432 ||| NN
of  ||| S:432 E:435 ||| IN
clotting  ||| S:435 E:444 ||| JJ
factor ||| S:444 E:450 ||| NN
,  ||| S:450 E:452 ||| ,
we  ||| S:452 E:455 ||| PRP
aimed  ||| S:455 E:461 ||| VBD
at  ||| S:461 E:464 ||| IN
highlighting  ||| S:464 E:477 ||| VBG
the  ||| S:477 E:481 ||| DT
experience  ||| S:481 E:492 ||| NN
of  ||| S:492 E:495 ||| IN
surgical  ||| S:495 E:504 ||| JJ
treatment  ||| S:504 E:514 ||| NN
in  ||| S:514 E:517 ||| IN
inhibitor  ||| S:517 E:527 ||| JJ
patients ||| S:527 E:535 ||| NNS
.  ||| S:535 E:537 ||| .
We  ||| S:537 E:540 ||| PRP
analyzed  ||| S:540 E:549 ||| VBD
the  ||| S:549 E:553 ||| DT
indications ||| S:553 E:564 ||| NNS
,  ||| S:564 E:566 ||| ,
types  ||| S:566 E:572 ||| NNS
of  ||| S:572 E:575 ||| IN
performed  ||| S:575 E:585 ||| JJ
interventions  ||| S:585 E:599 ||| NNS
and  ||| S:599 E:603 ||| CC
outcomes ||| S:603 E:611 ||| NNS
.  ||| S:611 E:613 ||| .
This  ||| S:613 E:618 ||| DT
single  ||| S:618 E:625 ||| JJ
center ||| S:625 E:631 ||| NN
,  ||| S:631 E:633 ||| ,
retrospective  ||| S:633 E:647 ||| JJ
analysis  ||| S:647 E:656 ||| NN
has  ||| S:656 E:660 ||| VBZ
been  ||| S:660 E:665 ||| VBN
conducted  ||| S:665 E:675 ||| VBN
on  ||| S:675 E:678 ||| IN
7  ||| S:678 E:680 ||| CD
inhibitor  ||| S:680 E:690 ||| CD
patients  ||| S:690 E:699 ||| NNS
registered  ||| S:699 E:710 ||| VBN
and  ||| S:710 E:714 ||| CC
treated  ||| S:714 E:722 ||| VBN
in  ||| S:722 E:725 ||| IN
Haemophilia  ||| S:725 E:737 ||| NNP
Center  ||| S:737 E:744 ||| NNP
of  ||| S:744 E:747 ||| IN
Timisoara  ||| S:747 E:757 ||| NNP
over  ||| S:757 E:762 ||| IN
ten  ||| S:762 E:766 ||| JJ
years  ||| S:766 E:772 ||| NNS
( ||| S:772 E:773 ||| -LRB-
1997-2007 ||| S:773 E:782 ||| NNP
) ||| S:782 E:783 ||| -RRB-
:  ||| S:783 E:785 ||| :
six  ||| S:785 E:789 ||| CD
patients  ||| S:789 E:798 ||| NNS
with  ||| S:798 E:803 ||| IN
severe  ||| S:803 E:810 ||| JJ
hemophilia  ||| S:810 E:821 ||| NNS
A  ||| S:821 E:823 ||| DT
( ||| S:823 E:824 ||| -LRB-
3  ||| S:824 E:826 ||| LS
-  ||| S:826 E:828 ||| :
high  ||| S:828 E:833 ||| JJ
titer ||| S:833 E:838 ||| NN
,  ||| S:838 E:840 ||| ,
3  ||| S:840 E:842 ||| LS
-  ||| S:842 E:844 ||| :
low  ||| S:844 E:848 ||| JJ
titer ||| S:848 E:853 ||| NN
) ||| S:853 E:854 ||| -RRB-
,  ||| S:854 E:856 ||| ,
one  ||| S:856 E:860 ||| CD
patient  ||| S:860 E:868 ||| NN
with  ||| S:868 E:873 ||| IN
von  ||| S:873 E:877 ||| NNP
Willebrand  ||| S:877 E:888 ||| NNP
disease  ||| S:888 E:896 ||| NN
( ||| S:896 E:897 ||| -LRB-
low  ||| S:897 E:901 ||| JJ
titer ||| S:901 E:906 ||| NN
) ||| S:906 E:907 ||| -RRB-
.Three  ||| S:907 E:914 ||| CD
patients  ||| S:914 E:923 ||| NNS
developed  ||| S:923 E:933 ||| VBD
inhibitors  ||| S:933 E:944 ||| VBN
only  ||| S:944 E:949 ||| RB
after  ||| S:949 E:955 ||| IN
2-5  ||| S:955 E:959 ||| CD
days  ||| S:959 E:964 ||| NNS
post  ||| S:964 E:969 ||| NN
surgery ||| S:969 E:976 ||| NN
.  ||| S:976 E:978 ||| .
A  ||| S:978 E:980 ||| DT
total  ||| S:980 E:986 ||| NN
of  ||| S:986 E:989 ||| IN
15  ||| S:989 E:992 ||| CD
invasive  ||| S:992 E:1001 ||| CD
procedures  ||| S:1001 E:1012 ||| NNS
were  ||| S:1012 E:1017 ||| VBD
carried  ||| S:1017 E:1025 ||| VBN
out ||| S:1025 E:1028 ||| RP
:  ||| S:1028 E:1030 ||| :
2  ||| S:1030 E:1032 ||| CD
orthopedic  ||| S:1032 E:1043 ||| CD
interventions  ||| S:1043 E:1057 ||| NNS
( ||| S:1057 E:1058 ||| -LRB-
1  ||| S:1058 E:1060 ||| CD
arthrodesis ||| S:1060 E:1071 ||| NN
,  ||| S:1071 E:1073 ||| ,
1  ||| S:1073 E:1075 ||| CD
arthroscopic  ||| S:1075 E:1088 ||| CD
synovectomy ||| S:1088 E:1099 ||| CD
) ||| S:1099 E:1100 ||| -RRB-
,  ||| S:1100 E:1102 ||| ,
2  ||| S:1102 E:1104 ||| CD
urogenital  ||| S:1104 E:1115 ||| CD
interventions  ||| S:1115 E:1129 ||| NNS
( ||| S:1129 E:1130 ||| -LRB-
1  ||| S:1130 E:1132 ||| CD
surgical  ||| S:1132 E:1141 ||| JJ
testicular  ||| S:1141 E:1152 ||| JJ
detorsion ||| S:1152 E:1161 ||| NN
,  ||| S:1161 E:1163 ||| ,
1  ||| S:1163 E:1165 ||| CD
orchiectomy ||| S:1165 E:1176 ||| CD
) ||| S:1176 E:1177 ||| -RRB-
,  ||| S:1177 E:1179 ||| ,
4  ||| S:1179 E:1181 ||| CD
limb  ||| S:1181 E:1186 ||| CD
amputations  ||| S:1186 E:1198 ||| NNS
( ||| S:1198 E:1199 ||| -LRB-
2  ||| S:1199 E:1201 ||| CD
bilateral  ||| S:1201 E:1211 ||| JJ
upper  ||| S:1211 E:1217 ||| JJ
and  ||| S:1217 E:1221 ||| CC
2  ||| S:1221 E:1223 ||| CD
lower  ||| S:1223 E:1229 ||| JJR
limb  ||| S:1229 E:1234 ||| JJ
amputation ||| S:1234 E:1244 ||| NN
) ||| S:1244 E:1245 ||| -RRB-
,  ||| S:1245 E:1247 ||| ,
2  ||| S:1247 E:1249 ||| CD
pseudotumour  ||| S:1249 E:1262 ||| NNS
( ||| S:1262 E:1263 ||| -LRB-
PT ||| S:1263 E:1265 ||| NNP
)  ||| S:1265 E:1267 ||| -RRB-
surgery  ||| S:1267 E:1275 ||| NN
interventions ||| S:1275 E:1288 ||| NNS
,  ||| S:1288 E:1290 ||| ,
5  ||| S:1290 E:1292 ||| CD
drainages  ||| S:1292 E:1302 ||| NNS
( ||| S:1302 E:1303 ||| -LRB-
2  ||| S:1303 E:1305 ||| CD
massive  ||| S:1305 E:1313 ||| JJ
pyohaemothorax ||| S:1313 E:1327 ||| NN
,  ||| S:1327 E:1329 ||| ,
1  ||| S:1329 E:1331 ||| CD
drainage  ||| S:1331 E:1340 ||| NN
of  ||| S:1340 E:1343 ||| IN
shank  ||| S:1343 E:1349 ||| JJ
haematoma ||| S:1349 E:1358 ||| NN
,  ||| S:1358 E:1360 ||| ,
1  ||| S:1360 E:1362 ||| CD
drainage  ||| S:1362 E:1371 ||| NN
of  ||| S:1371 E:1374 ||| IN
compressive  ||| S:1374 E:1386 ||| JJ
forearm  ||| S:1386 E:1394 ||| JJ
haematoma ||| S:1394 E:1403 ||| NN
,  ||| S:1403 E:1405 ||| ,
1  ||| S:1405 E:1407 ||| CD
drainage  ||| S:1407 E:1416 ||| NN
of  ||| S:1416 E:1419 ||| IN
thigh  ||| S:1419 E:1425 ||| JJ
haematoma ||| S:1425 E:1434 ||| NN
) ||| S:1434 E:1435 ||| -RRB-
.  ||| S:1435 E:1437 ||| .
Haemostasis  ||| S:1437 E:1449 ||| NNP
was  ||| S:1449 E:1453 ||| VBD
achieved  ||| S:1453 E:1462 ||| VBN
in  ||| S:1462 E:1465 ||| IN
patients  ||| S:1465 E:1474 ||| NNS
with  ||| S:1474 E:1479 ||| IN
low  ||| S:1479 E:1483 ||| JJ
level  ||| S:1483 E:1489 ||| NN
inhibitors  ||| S:1489 E:1500 ||| NNS
(  ||| S:1500 E:1501 ||| -LRB-
< ||| S:1501 E:1503 ||| SYM
5  ||| S:1503 E:1505 ||| CD
BU ||| S:1505 E:1507 ||| CD
/ ||| S:1507 E:1508 ||| CD
ml ||| S:1508 E:1510 ||| CD
)  ||| S:1510 E:1512 ||| -RRB-
with  ||| S:1512 E:1517 ||| IN
high  ||| S:1517 E:1522 ||| JJ
doses  ||| S:1522 E:1528 ||| NNS
of  ||| S:1528 E:1531 ||| IN
FVIII  ||| S:1531 E:1537 ||| NNP
concentrates ||| S:1537 E:1549 ||| VBZ
;  ||| S:1549 E:1551 ||| :
in  ||| S:1551 E:1554 ||| IN
those  ||| S:1554 E:1560 ||| DT
with  ||| S:1560 E:1565 ||| IN
high  ||| S:1565 E:1570 ||| JJ
inhibitor  ||| S:1570 E:1580 ||| JJ
level  ||| S:1580 E:1586 ||| NN
( ||| S:1586 E:1587 ||| -LRB-
>  ||| S:1587 E:1589 ||| CD
5  ||| S:1589 E:1591 ||| CD
BU ||| S:1591 E:1593 ||| CD
/ ||| S:1593 E:1594 ||| CD
ml ||| S:1594 E:1596 ||| CD
) ||| S:1596 E:1597 ||| -RRB-
,  ||| S:1597 E:1599 ||| ,
surgery  ||| S:1599 E:1607 ||| NN
was  ||| S:1607 E:1611 ||| VBD
managed  ||| S:1611 E:1619 ||| VBN
using  ||| S:1619 E:1625 ||| VBG
by-passing  ||| S:1625 E:1636 ||| JJ
agents ||| S:1636 E:1642 ||| NNS
.  ||| S:1642 E:1644 ||| .
Supplementation  ||| S:1644 E:1660 ||| NNP
with  ||| S:1660 E:1665 ||| IN
local  ||| S:1665 E:1671 ||| JJ
fibrin  ||| S:1671 E:1678 ||| JJ
glue  ||| S:1678 E:1683 ||| NN
and  ||| S:1683 E:1687 ||| CC
intravenous  ||| S:1687 E:1699 ||| NNS
or  ||| S:1699 E:1702 ||| CC
local  ||| S:1702 E:1708 ||| JJ
antifibrinolytic  ||| S:1708 E:1725 ||| JJ
agents  ||| S:1725 E:1732 ||| NNS
was  ||| S:1732 E:1736 ||| VBD
given  ||| S:1736 E:1742 ||| VBN
in  ||| S:1742 E:1745 ||| IN
68.75 ||| S:1745 E:1750 ||| CD
%  ||| S:1750 E:1752 ||| NN
of  ||| S:1752 E:1755 ||| IN
interventions ||| S:1755 E:1768 ||| NNS
.  ||| S:1768 E:1770 ||| .
Postoperative  ||| S:1770 E:1784 ||| JJ
complications  ||| S:1784 E:1798 ||| NNS
consisted  ||| S:1798 E:1808 ||| VBD
of  ||| S:1808 E:1811 ||| IN
haemorrhagic  ||| S:1811 E:1824 ||| JJ
shock  ||| S:1824 E:1830 ||| NN
in  ||| S:1830 E:1833 ||| IN
13.33 ||| S:1833 E:1838 ||| CD
%  ||| S:1838 E:1840 ||| NN
of  ||| S:1840 E:1843 ||| IN
interventions  ||| S:1843 E:1857 ||| NNS
and  ||| S:1857 E:1861 ||| CC
infection  ||| S:1861 E:1871 ||| NN
in  ||| S:1871 E:1874 ||| IN
6.66 ||| S:1874 E:1878 ||| CD
% ||| S:1878 E:1879 ||| NN
.  ||| S:1879 E:1881 ||| .
Haemostatic  ||| S:1881 E:1893 ||| JJ
outcome  ||| S:1893 E:1901 ||| NN
was  ||| S:1901 E:1905 ||| VBD
evaluated  ||| S:1905 E:1915 ||| VBN
by  ||| S:1915 E:1918 ||| IN
blood  ||| S:1918 E:1924 ||| NN
loss  ||| S:1924 E:1929 ||| NN
and  ||| S:1929 E:1933 ||| CC
duration  ||| S:1933 E:1942 ||| NN
of  ||| S:1942 E:1945 ||| IN
treatment ||| S:1945 E:1954 ||| NN
,  ||| S:1954 E:1956 ||| ,
compared  ||| S:1956 E:1965 ||| VBN
to  ||| S:1965 E:1968 ||| TO
expectations  ||| S:1968 E:1981 ||| NNS
for  ||| S:1981 E:1985 ||| IN
non-inhibitor  ||| S:1985 E:1999 ||| JJ
patients ||| S:1999 E:2007 ||| NNS
.  ||| S:2007 E:2009 ||| .
The  ||| S:2009 E:2013 ||| DT
outcome  ||| S:2013 E:2021 ||| NN
was  ||| S:2021 E:2025 ||| VBD
excellent  ||| S:2025 E:2035 ||| JJ
and  ||| S:2035 E:2039 ||| CC
good  ||| S:2039 E:2044 ||| JJ
in  ||| S:2044 E:2047 ||| IN
66.66 ||| S:2047 E:2052 ||| CD
%  ||| S:2052 E:2054 ||| NN
of  ||| S:2054 E:2057 ||| IN
interventions ||| S:2057 E:2070 ||| NNS
,  ||| S:2070 E:2072 ||| ,
and  ||| S:2072 E:2076 ||| CC
fair  ||| S:2076 E:2081 ||| JJ
in  ||| S:2081 E:2084 ||| IN
33.33 ||| S:2084 E:2089 ||| CD
% ||| S:2089 E:2090 ||| NN
.  ||| S:2090 E:2092 ||| .
Discussion ||| S:2092 E:2102 ||| NN
,  ||| S:2102 E:2104 ||| ,
conclusion ||| S:2104 E:2114 ||| NN
:  ||| S:2114 E:2116 ||| :
Indication  ||| S:2116 E:2127 ||| NNP
of  ||| S:2127 E:2130 ||| IN
invasive  ||| S:2130 E:2139 ||| JJ
procedures  ||| S:2139 E:2150 ||| NNS
in  ||| S:2150 E:2153 ||| IN
haemophiliacs  ||| S:2153 E:2167 ||| NN
with  ||| S:2167 E:2172 ||| IN
inhibitors  ||| S:2172 E:2183 ||| NN
was  ||| S:2183 E:2187 ||| VBD
limited  ||| S:2187 E:2195 ||| VBN
to  ||| S:2195 E:2198 ||| TO
life  ||| S:2198 E:2203 ||| NN
and ||| S:2203 E:2206 ||| CC
/ ||| S:2206 E:2207 ||| NNP
or  ||| S:2207 E:2210 ||| CC
limb-threatening  ||| S:2210 E:2227 ||| JJ
situations ||| S:2227 E:2237 ||| NNS
.  ||| S:2237 E:2239 ||| .
In  ||| S:2239 E:2242 ||| IN
low-income  ||| S:2242 E:2253 ||| JJ
countries ||| S:2253 E:2262 ||| NNS
,  ||| S:2262 E:2264 ||| ,
inhibitor  ||| S:2264 E:2274 ||| NN
and  ||| S:2274 E:2278 ||| CC
recovery  ||| S:2278 E:2287 ||| NN
of  ||| S:2287 E:2290 ||| IN
FVIII  ||| S:2290 E:2296 ||| NNP
monitoring  ||| S:2296 E:2307 ||| NN
is  ||| S:2307 E:2310 ||| VBZ
mandatory  ||| S:2310 E:2320 ||| JJ
in  ||| S:2320 E:2323 ||| IN
the  ||| S:2323 E:2327 ||| DT
postoperative  ||| S:2327 E:2341 ||| JJ
follow-up  ||| S:2341 E:2351 ||| NN
of  ||| S:2351 E:2354 ||| IN
patients  ||| S:2354 E:2363 ||| NNS
with  ||| S:2363 E:2368 ||| IN
low  ||| S:2368 E:2372 ||| JJ
or  ||| S:2372 E:2375 ||| CC
no  ||| S:2375 E:2378 ||| DT
substitution  ||| S:2378 E:2391 ||| JJ
prior  ||| S:2391 E:2397 ||| JJ
to  ||| S:2397 E:2400 ||| TO
surgery  ||| S:2400 E:2408 ||| VB
due  ||| S:2408 E:2412 ||| JJ
to  ||| S:2412 E:2415 ||| TO
false  ||| S:2415 E:2421 ||| JJ
negative  ||| S:2421 E:2430 ||| JJ
results  ||| S:2430 E:2438 ||| NNS
at  ||| S:2438 E:2441 ||| IN
the  ||| S:2441 E:2445 ||| DT
preoperative  ||| S:2445 E:2458 ||| JJ
investigation ||| S:2458 E:2471 ||| NN
.  ||| S:2471 E:2473 ||| .
